touchMDT

Biomarker-guided management of NSCLC: Current and future strategies

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Lung Cancer, Thoracic Oncology Watch Time: 46 mins

touchMDT Biomarker-guided management of NSCLC: Current and future strategies

Select a discussion in the hub to watch our multidisciplinary faculty share their insights on biomarker testing methods and interpretation of results to guide treatment selection for a patient with advanced NSCLC.

Overview & Learning Objectives

Jenny is a 71-year-old female diagnosed with advanced NSCLC. How can biomarker testing help to select the optimal treatment?

Medical Oncologist & Pulmonologist

A medical oncologist and a pulmonologist assess the need for biomarker testing for Jenny after her diagnosis of advanced NSCLC

Expert Spotlight
Prof. S Popat
Royal Marsden Hospital, London, UK
Prof. Dr. E Smit
Netherlands Cancer Institute, Amsterdam, The Netherlands

Prof. Sanjay Popat and Prof. Dr. Egbert Smit discuss the clinical assessment of a 71-year old patient, Jenny, who has been diagnosed with stage IV non-small cell lung cancer (NSCLC). They highlight the importance of biomarker testing and consider how current recommendations can be implemented into clinical practice.

Learn more Back to MDT Hub Time: 11:04
 
Medical Oncologist & Pathologist

A medical oncologist and a pathologist discuss the benefits and limitations of different biomarker testing methods

Expert Spotlight
Prof. S Popat
Royal Marsden Hospital, London, UK
Prof. P Hofman
Nice Sophia Antipolis University, Nice, France

Prof. Sanjay Popat and Prof. Paul Hofman review different biomarker testing methods for Jenny, a 71-year-old patient who has been diagnosed with stage IV non-small cell lung cancer (NSCLC). They discuss the benefits and limitations of potential approaches and consider how the oncologist and pathologist can work collaboratively to reach a decision.

Learn more Back to MDT Hub Time: 12:25
 
Medical Oncologist & Pulmonologist

A medical oncologist and a pulmonologist use biomarker test results to guide treatment selection

Expert Spotlight
Prof. S Popat
Royal Marsden Hospital, London, UK
Prof. Dr. E Smit
Netherlands Cancer Institute, Amsterdam, The Netherlands

Prof. Sanjay Popat and Prof. Dr. Egbert Smit discuss the biomarker testing results for Jenny, a 71-year-old patient with stage IV non-small cell lung cancer (NSCLC). They consider the potential treatment options in light of her recent biomarker results. 

Learn more Back to MDT Hub Time: 10:09
 
Medical Oncologist, Pulmonologist & Oncology Nurse Clinician

The MDT reviews Jenny’s journey from diagnosis to treatment to discuss how they can work together to deliver personalized care

Expert Spotlight
Prof. S Popat
Royal Marsden Hospital, London, UK
Prof. Dr. E Smit
Netherlands Cancer Institute, Amsterdam, The Netherlands
Ms J Fenemore
The Christie Hospital, Manchester, UK

Prof. Sanjay Popat is joined by Prof. Dr. Egbert Smit and Ms Jackie Fenemore to discuss how the multidisciplinary team (MDT) delivers personalized care to optimize clinical outcomes for patients with advanced non-small cell lung cancer (NSCLC). They explore the case of Jenny, a 71-year-old patient with stage IV NSCLC, and discuss the role of each MDT member in communicating Jenny’s biomarker results and recommended treatment to her.

Learn more Back to MDT Hub Time: 13:03
 
Back To Top
Overview & Learning Objectives
Overview

Join some of the members of a lung cancer multidisciplinary team (MDT) as they perform clinical assessments and biomarker testing to guide treatment selection for Jenny, a 71-year-old patient with advanced non-small cell lung cancer (NSCLC).

Learning Objectives

After watching this activity, participants should be better able to:

  • Discuss current recommendations for biomarker testing in patients with advanced NSCLC
  • Identify the most appropriate biomarker testing methods for each patient with advanced NSCLC
  • Use biomarker testing results to select appropriate targeted and immuno-oncological treatment options for patients with advanced NSCLC
Faculty & Disclosures
Prof. Sanjay Popat

Royal Marsden Hospital, London, UK

Sanjay Popat is a consultant thoracic medical oncologist at the Royal Marsden Hospital and Professor of Thoracic Oncology at the Institute of Cancer Research, London, UK.

His research interests include the development of novel drug strategies for the treatment of thoracic cancers through clinical trials, the identification of DNA variants that influence thoracic cancer development and their impact on clinical behaviour, as well as the identification of biomarkers predictive of therapeutic effect.

He is Co-Director for the National Institute for Human Research (NIHR) London South Clinical Research Network (CRN) Cancer Division and Chair of Cancer for the West London Genomic Medicine Centre. He chairs the British Thoracic Oncology Group (BTOG) and is the immediate past Chair of the UK National Cancer Research Institute (NCRI) Lung Cancer Clinical Studies Group (CSG) Advanced Disease Sub-group. He is active in the European Thoracic Oncology Platform (ETOP) and the European Organization for Research and Treatment of Cancer (EORTC) Lung Group.

Prof. Sanjay Popat discloses: Honoraria from AstraZeneca, Boehringer Ingelheim, Chugai Pharma, Roche and Takeda; Consulting or advisory role for AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Guardant Health, Merck Sharp & Dohme, Novartis, Pfizer, Roche and Takeda; Travel, accommodations/expenses from Boehringer Ingelheim, Bristol Myers Squibb and Merck Sharp & Dohme; Research funding from (all fees to institution) Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Epizyme, Lilly, Roche and Takeda.

Prof. Dr. Egbert Smit

Netherlands Cancer Institute and Vrije Universiteit Medical Centre, Amsterdam, The Netherlands

Egbert Smit is Professor of Pulmonary Medicine (with an emphasis on pulmonary oncology) at the Netherlands Cancer Institute, Department of Thoracic Oncology and the Department of Pulmonary Diseases of the Vrije Universiteit Medical Centre in Amsterdam, The Netherlands.

Since 1986 he has been involved in basic research and clinical trials ranging from chemoprevention of lung cancer to treatment of advanced non-small and small cell lung cancer (NSCLC and SCLC). He has been a principal investigator for several national and international phase II and III trials.

Over the past decade, the focus of his research has been on translational oncology and molecular imaging. These research activities have resulted in over 300 publications in peer-reviewed journals and chapters in books.

Prof. Dr. Smit is active in several national and international societies such as the International Association for the Study of Lung Cancer (IASLC), the European Organization for Research and Treatment of Cancer (EORTC), the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). He served as the chair of a multidisciplinary task force for the development of clinical guidelines in SCLC in The Netherlands. Since 2011, he has been a member of the European Society for Medical Oncology (ESMO) Lung and other Thoracic Tumours Faculty Group. He is on the review board of several major oncology journals and has co-organized several national meetings on thoracic oncology and (post) graduate teaching courses.

Prof. Dr. Egbert Smit discloses (all fees to institution): Speaker and advisory board fees from AstraZeneca, Bayer, Bristol Myers Squibb, Cellgene, DSI, Eli Lilly, Merck KGaA, Merck Sharp & Dohme, Novartis, Pfizer, Regeneron, Roche Diagnostics, Roche Genentech and Takeda; Research support from AstraZeneca, Bristol Myers Squibb, Merck KGaA, Merck Sharp & Dohme and Roche Genentech; Principal investigator for clinical studies sponsored by Amgen, Bayer, Clovis, Eli Lilly, Novartis, PharmaMar, Roche Genentech and Takeda.

Prof. Paul Hofman

Nice Sophia Antipolis University, Nice, France

Paul Hofman is Director of the Inserm Research Team (circulating tumour cells and lung cancer metastases) at the Institute for Research on Cancer and Aging in Nice (IRCAN) of Nice Sophia Antipolis University in Nice, France. Since 1996, he has been Professor of Pathology. He is Head of the Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur in Nice, Director of the OncoAge consortium (www.oncoage.org) and Head of the Côte d’Azur Biobank (www.biobank-cotedazur.fr).

He trained at the Brigham and Women’s Hospital (Harvard Medical School, Boston) from 1992 to 1995 and at the Max Planck Institut (Tübingen) from 1996 to 1997. He has authored and co-authored more than 600 publications.

Prof. Paul Hofman discloses: Consulting or advisory role for AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Bristol Myers Squibb, Illumina, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Roche and Thermo Fisher; Meetings and presentations for AbbVie, Amgen, AstraZeneca, Bayer, Biocartis, Bristol Myers Squibb, Illumina, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Pierre Fabre, Roche and Thermo Fisher.

Ms Jackie Fenemore

The Christie Hospital, Manchester, UK

Jackie Fenemore is a lung cancer nurse clinician at The Christie Hospital in Manchester, UK. She qualified as a registered general nurse (RGN) in 1995 and has worked at The Christie Hospital, Manchester for over 26 years.

She worked as a lung cancer nurse specialist from 2007 to 2017. After qualifying as a non-medical prescriber in 2009 and completing an MSc in Advanced Practice in 2017, she continued to practise as a lung cancer nurse clinician. She was the Lung Cancer Nursing UK (LCNUK) representative of the British Thoracic Oncology Group (BTOG) Steering Group, and is currently Chair of the LCNUK Committee.

Ms Jackie Fenemore discloses: Advisory board role for Lilly, Merck Sharp & Dohme and Novartis; Speaker for Amgen, Astrazeneca, Lilly, Merck Sharp & Dohme and Takeda; Educational grant from Takeda.

Downloads

View and download resources from this activity to support your learning and share with colleagues

Register to touchRESPIRATORY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Register For Free Now

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchMDT on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72